Reata Announces the Presentation of the Pivotal MOXIe Part 2 Study of Omaveloxolone in Friedreich’s Ataxia at the American ...
September 03 2020 - 5:45AM
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,”
or “we”), a clinical-stage biopharmaceutical company, today
announced the forthcoming presentation of efficacy and safety
results from the pivotal MOXIe Part 2 study, a randomized,
double-blind, placebo-controlled trial of omaveloxolone in
Friedreich’s ataxia.
The presentation will take place on September
24, 2020 as part of the 2020 Emerging Science presentations hosted
by the American Academy of Neurology (AAN). David Lynch,
M.D., Ph.D., will present the data. Dr. Lynch is an attending
physician at the Children’s Hospital of Philadelphia (CHOP),
professor of neurology at the Perelman School of Medicine at the
University of Pennsylvania, and the principal investigator of the
MOXIe study.
The AAN Science Committee selected this as one
of 12 late-breaking abstracts, chosen from more than 150 abstracts
submitted to the April 2020 AAN meeting, which was converted to a
virtual meeting due to the COVID-19 pandemic. More
information about the AAN presentation can be found at the AAN
Emerging Science webpage:
https://www.aan.com/education-and-research/research/2020-aan-science-highlights/.
Separately, Dr. Lynch will present the results
of the MOXIe Part 2 study at the FARA 2020 Biomarker & Clinical
Endpoint Meeting, also scheduled for September 24. More
information about this meeting and Dr. Lynch’s presentation there
can be found at
https://curefa.org/pdf/research/Agenda-Biomarker2020-draft.pdf.
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and inflammation.
Reata’s two most advanced clinical candidates,
bardoxolone methyl ("bardoxolone") and omaveloxolone, target
the important transcription factor Nrf2 that promotes the
resolution of inflammation by restoring mitochondrial function,
reducing oxidative stress, and inhibiting pro-inflammatory
signaling. Bardoxolone and omaveloxolone are
investigational drugs, and their safety and efficacy have not been
established by any agency.
Contact:Reata Pharmaceuticals, Inc.(972)
865-2219http://reatapharma.com
Investors:Vinny JindalVice President, Investor
Relations and Corporate Communications(469)
374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” including, without
limitation, statements regarding the success, cost and timing of
our product development activities and clinical trials, our plans
to research, develop and commercialize our product candidates, our
plans to submit regulatory filings, and our ability to obtain and
retain regulatory approval of our product candidates. You can
identify forward-looking statements because they contain words such
as “believes,” “will,” “may,” “aims,” “plans,” “model,” and
“expects.” Forward-looking statements are based on Reata’s
current expectations and assumptions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks, and changes in circumstances that may differ
materially from those contemplated by the forward-looking
statements, which are neither statements of historical fact nor
guarantees or assurances of future performance. Important
factors that could cause actual results to differ materially from
those in the forward-looking statements include, but are not
limited to, (i) the timing, costs, conduct, and outcome of our
clinical trials and future preclinical studies and clinical trials,
including the timing of the initiation and availability of data
from such trials; (ii) the timing and likelihood of regulatory
filings and approvals for our product candidates; (iii) whether
regulatory authorities determine that additional trials or data are
necessary in order to obtain approval; (iv) the potential market
size and the size of the patient populations for our product
candidates, if approved for commercial use, and the market
opportunities for our product candidates; and (v) other factors set
forth in Reata’s filings with the U.S. Securities and Exchange
Commission, including the detailed factors discussed under the
caption “Risk Factors” in its Annual Report on Form 10-K for the
fiscal year ended December 31, 2019. The forward-looking
statements speak only as of the date made and, other than as
required by law, we undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Apr 2023 to Apr 2024